Renal Denervation Market Research Report: by Product (Symplicity, Vessix (V2), EnligHTN, Paradise, Iberis, Others), by Technology (Radiofrequency, Ultrasound, Micro-infusion, and Others), by End-user (Hospitals, Clinics, Ambulatory Surgical Centers, and Others), and Region - Forecast To 2030
ID: MRFR/MED/5249-HCR | February 2021 | Region: Global | 115 pages
Speak to Analyst
Request a Free Sample
Renal Denervation Market Overview:
The renal denervation market is expected to rise at a solid CAGR of 38.60% over the 2020-2030 forecast period, with the market’s value rising from USD 200 million in 2017 to USD 11,488.51 million in 2030.
The renal Denervation Market is majorly driven by the rising prevalence of hypertension across the world. According to the CDC, the prevalence of hypertension was close to 26% among adults aged 20 years or more in 2000. There has been a 5.2% increase in the prevalence of hypertension over the next ten years, making it a prime concern for the healthcare sector in countries across the globe. Developed countries have been proactive in taking measures to counteract and reduce the prevalence of hypertension among their population, leading to growing support for the renal denervation market.
Renal denervation is a minimally invasive procedure aimed at treating resistant hypertension. The process uses RF or ultrasound ablation upon nerves in the renal artery to reduce sympathetic activity in the kidney and reduce blood pressure.
The growing awareness among people in developing countries and steady growth of the healthcare infrastructure in APAC is another major driver for the renal denervation market. APAC countries have taken massive steps towards bridging the gap between themselves and developed western countries in terms of the technological advancement and sophistication of their healthcare sectors in recent years. Countries such as China and India have announced major initiatives to aid the growth of the healthcare sector, leading to steady growth of the renal denervation market. The steady growth of healthcare infrastructure in APAC countries is likely to be a major driver for the renal denervation market over the forecast period, as hypertension is on the rise in Southeast Asian countries and needs proactive measures to keep it in check.
The rising preference to minimally invasive procedures among the populace is also a major driver for the renal denervation market. The risk minimization achieved in minimally invasive procedures has made them popular among customers, and governments are also supporting the growing adoption of minimally invasive procedures by making it easier to incorporate minimally invasive procedures into the healthcare sector’s processes. This is likely to be a major driver for the renal denervation market over the forecast period.
Major Key Players Competitive Analysis:
Leading players in the renal denervation market include Boston Scientific, Medtronic, ReCor Medical, St. Jude Medical, Cardiosonic, Cordis, Kona Medical, Sound Intervention, and Terumo.
The renal denervation market is hamstrung by challenging government regulations in regions such as the U.S. Medtronic recently announced the launch of a new placebo-controlled randomized clinical trial in an effort to get regulatory approval in the U.S., a major commercial market for high blood pressure remedies.
Segmentation:
The renal denervation market is segmented on the basis of product, technology, and end use.
By product, the renal denervation market is segmented into Symplicity, Vessix (V2), EnligHTN, Paradise, Iberis, and others. Symplicity holds the largest market share in the renal denervation market at present and is likely to remain a leading contributor over the forecast period. However, Paradise is likely to be the fastest growing product segment in the renal denervation market over the forecast period.
On the basis of technology, the renal denervation market is divided into radiofrequency, ultrasound, micro-infusion, and others. Radiofrequency is likely to be the fastest growing segment over the forecast period, eclipsing ultrasound, the largest market segment at present, in terms of growth rate.
By end user, the renal denervation market is segmented into hospitals, clinics, ambulatory surgical centers, and others. Hospitals are the largest segment in the global renal denervation market, while ambulatory surgical centers are expected to exhibit the fastest growth over the forecast period.
By region, the renal denervation market is segmented into North America, Europe, Asia Pacific (APAC), and Rest of the world.
By Product
- Symplicity
- Vessix (V2)
- EnligHTN
- Paradise
- Iberis
- Others
By Technology
- Radiofrequency
- Ultrasound
- Micro-infusion
- Others
By End-user
- Hospitals
- Clinics
- Ambulatory Surgical Centers
- Others
Report Methodology
Accuracy of the data has been maintained at all cost in the report. The report contains information gathered from primary interviews with the industry’s leading lights as well as information gathered from reliable secondary research. The research is carried out according to a domain-specific formula to ensure the accuracy of the data gathered. A comprehensive look at the market is provided through the report’s granular look at the market’s segmentation, and the use of a top-down and bottom-up approach supports this premise
Report Scope:
| Report Attribute/Metric | Details |
|---|---|
| Market Size |
|
| CAGR | 38.60% (2020-2030) |
| Base Year | 2019 |
| Forecast Period | 2020-2030 |
| Historical Data | 2018 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product, Technology, and End use |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Boston Scientific, Medtronic, ReCor Medical, St. Jude Medical, Cardiosonic, Cordis, Kona Medical, Sound Intervention, and Terumo |
| Key Market Opportunities | New product launches and R&D Amongst major key Players |
| Key Market Drivers |
|
